http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arrowhead to Present at Barclays Global Healthcare Conference 2018
-
Arrowhead Pharmaceuticals Corp (ARWR) Reports Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Pharmaceuticals Corp (ARWR) Confirms Orphan Drug Status for ARO-AAT
-
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
-
Arrowhead Pharmaceuticals Corp (ARWR) Says it Was Cleared to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
-
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
-
Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results
-
Arrowhead Pharmaceuticals Corp (ARWR) Appoints William Waddill to Board of Directors
-
Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors
-
Arrowhead Pharmaceuticals Corp (ARWR) Files for Clearance to Start Phase 1/2 Study of ARO-HBV
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV
-
Arrowhead Pharmaceuticals Corp (ARWR) Announces Filing of Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4)
-
Arrowhead Pharmaceuticals Reports Fiscal 2017 Year End Results
-
Arrowhead (ARWR) Presents New Data Showing Sustained Host Response in HBV Patients Following RNAi Therapy
-
Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy
-
Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results
-
Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Corp (ARWR) Reports Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease
-
Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017
-
Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
-
Arrowhead to Present at Chardan Gene Therapy Conference
-
Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
-
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
-
Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
-
Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
-
Arrowhead Reports Fiscal 2017 Third Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
-
Arrowhead Reports Fiscal 2017 Second Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results
-
Arrowhead Research (ARWR) Presents ARC-AAT Clinical Data at ILC
-
Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™
-
Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™
-
Arrowhead Research (ARWR) Announces Presentations at ILC
-
Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
-
Arrowhead Research (ARWR) Adopts Stockholder Rights Agreement
-
Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement
-
Arrowhead Reports Fiscal 2017 First Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results
-
Arrowhead Research (ARWR) Says It's Had No Discussion on Potential Transaction with Silence
-
Arrowhead Provides Response to New Minority Shareholder Announcement
-
Arrowhead Reports Fiscal 2016 Year End Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results
-
Arrowhead Research (ARWR) to Discontinue ARC-520, ARC-521, and ARC-AAT Development; Will Cut Workforce
-
Arrowhead Pharmaceuticals Focuses Resources on Subcutaneous and Extra-Hepatic RNAi Therapeutics

